There is growing evidence that peptidic glucagon-like peptide-1 receptor agonists (GLP-1RA), such as exenatide, may provide useful therapeutic options for treatment of feline diabetes. However, because such drugs are administered subcutaneously, it is desirable that they be long-acting and not ...
The study compared the once-a-month form with Bydureon, which is to be taken once a week. “Results for A1C, fasting glucose, and weight in the exenatide once monthly treatment arms were generally comparable to those seen in the Bydureon reference arm,” the press release states. Today I ...
GLP-1 RA worldwide in patients with T2D2,a 7 Million patients prescribed worldwidea 7+ Years helping patients with T2D1 aSource: Based on internal analysis by Novo Nordisk using data from: IQVIA MIDAS®monthly volume sales data for 40 countries. Data period: Rolling 3-month time period ...
Drug update Dulaglutide: a once-weekly GLP-1 receptor agonist for type 2 diabetes Dulaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist that requires only once-weekly administration and has been shown to be an effective gluco... KE Neal,GR Fulcher - 《Medicine Today》 被引量:...
INDIANAPOLIS,June 23, 2023/PRNewswire/ --Eli Lilly and Company(NYSE: LLY) announced today new phase 2 data for orforglipron, its first nonpeptide oral glucagon-like peptide-1 (GLP-1) receptor agonist being studied for chronic weight management in participants with obesity or over...
glucagon-like peptide-1 agonistssemaglutideRetrospective database studies have shown that switching between some GLP-1RAs may be associated with additional benefits on glycemic control and body weight (BW).This prospective post hoc analysis of pooled data from the SURE real-world program (9 ~30 ...
(NYSE: PFE) announced that based on results from the ongoing pharmacokinetic study (NCT06153758), the company has selected its preferred once-daily modified release formulation for danuglipron, an oral glucagon-like peptide-1 (GLP-1) receptor agonist. Pfizer plans t...
FDA approved lixisenatide (Adlyxin, Sanofi-Aventis), a once-daily mealtime GLP-1 receptor agonist injection for type 2 diabetes, which will compete against the once-weekly pen dulaglutide (Trulicity, Eli Lilly) and the injectable liraglu... C Blank 被引量: 0发表: 2016年 Dulaglutide: Third on...
(QD) titrated up over 12 weeks. The primary endpoint is percent change in body weight from baseline to week 36. Secondary endpoints include safety and tolerability of the monthly titration scheme, as ...
Dose‐dependent effects of the once‐daily GLP‐1 receptor agonist lixisenatide in patients with Type 2 diabetes inadequately controlled with metformin: a randomized, double‐blind, placebo‐controlled trial[J] . R. E.Ratner,J.Rosenstock,G.Boka.Diabetic Medicine . 2010 (...